NCT01063660View on ClinicalTrials.gov

Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

PHASE2CompletedINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

March 31, 2004

Study Completion Date

July 31, 2007

Conditions

Acute Myeloid Leukaemia

Interventions

DRUG

Treosulfan

14 g/m²/d day -6 to -4

Trial Locations (1)

18057

University of Rostock, Rostock

All Listed Sponsors

lead

medac GmbH

INDUSTRY

NCT01063660 - Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML) | Biotech Hunter | Biotech Hunter